Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Who makes the decisions regarding the benefit status of medications listed in the Nova Scotia Formulary?

0
Posted

Who makes the decisions regarding the benefit status of medications listed in the Nova Scotia Formulary?

0

The Atlantic Expert Advisory Committee and the Canadian Expert Drug Advisory Committee make recommendations on the benefit status of drugs and supplies to the Department of Health and Wellness. These committees include medical specialists, family practitioners, and pharmacists. They consult experts in specialty areas as required. The benefit evaluation process typically begins when a manufacturer requests to have a product evaluated for benefits status. Guidelines list the information that the manufacturer must submit. Submission requirements for the Atlantic Common Drug Review process are available on this website and submission requirements for the Canadian Common Drug Review process are available on the Canadian Agency for Drugs and Technologies in Health website. Clinical studies are reviewed extensively. Coverage for new products is not available until this process is completed and the drug has been added to the benefit list. A drug may be added as a full benefit, denied any benef

Related Questions

Thanksgiving questions

*Sadly, we had to bring back ads too. Hopefully more targeted.